France Newborn Screening Software Market Size & Outlook, 2026-2034
France Newborn Screening Software Market Insights
- According to Reed Intelligence analysis, the France Newborn Screening Software Market size was USD 44.56 Million in 2025 and is projected to reach USD 89.27 Million by 2034.
- The France market is projected to grow at a CAGR of 8.1% between 2026 and 2034.
- By segment, Instruments emerged as the largest By Product in terms of market size in 2025.
- Reagents is anticipated to remain the most attractive By Product segment, recording the fastest growth during the forecast period.
![France Newborn Screening Software Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/france-newborn-screening-software-market-france-by-product-244422.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- France contributed 3.16% to the global Newborn Screening Software Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Newborn Screening Software Market.
- In Europe, Germany is projected to capture the leading share of market size by 2034.
- Among Europe markets, Nordic is expected to post the fastest growth, reaching USD 31.71 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 44.56 Million |
| Market Size In 2034 | USD 89.27 Million |
| Largest segment | Instruments |
| Units | Revenue in USD Million |
| CAGR | 8.1% (2026-2034) |
| Segmnetation Covered | |
| By Product |
|
| By Technology |
|
| By Test Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Newborn Screening Software Market By Product 2026-2034 (USD Million)
| By Product | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments | XX.x | XX.x | XX.x | 27.55 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reagents | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Newborn Screening Software Market By Technology 2026-2034 (USD Million)
| By Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tandem Mass Spectrometry | XX.x | XX.x | XX.x | 13.49 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pulse Oximetry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Enzyme Based Assay | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| DNA Assay | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Electrophoresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Newborn Screening Software Market By Test Type 2026-2034 (USD Million)
| By Test Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dry Blood Spot Test | XX.x | XX.x | XX.x | 22.04 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| CCHD | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hearing Screen | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.